
==== Front
Infect Dis Rep
Infect Dis Rep
idr
Infectious Disease Reports
2036-7430
2036-7449
MDPI

10.3390/idr16050060
idr-16-00060
Article
Comparative Epidemiological and Clinical Outcomes on COVID-19 and Seasonal Influenza Hospitalized Patients during 2023
Vlase Constantin-Marinel Conceptualization Software Formal analysis Investigation Writing – original draft 12
https://orcid.org/0000-0002-0626-2023
Stuparu Cretu Mariana Validation Data curation Writing – original draft Visualization Project administration 34*
Vasile Mihaela-Camelia Validation Investigation Data curation Writing – original draft 15
Popovici George-Cosmin Software Validation Formal analysis Writing – original draft 16
https://orcid.org/0000-0002-4762-0755
Arbune Manuela Conceptualization Methodology Investigation Resources Writing – review & editing Supervision 78
Rachiotis George Academic Editor
1 Doctoral Studies in Biomedical Sciences, “Dunarea de Jos” University Galati, 800008 Galati, Romania; constantin.vlase@ugal.ro (C.-M.V.); mihaela.vasile@ugal.ro (M.-C.V.); popovicigeorge1989@gmail.com (G.-C.P.)
2 Military Hospital “Dr. Aristide Serfioti” Galați, 800008 Galati, Romania
3 Medical Department, “Dunarea de Jos” University Galati, 800008 Galati, Romania
4 Clinic Emergency Children Hospital, 800487 Galati, Romania
5 Infectious Diseases Clinic II, Infectious Diseases Clinic Hospital Galati, 800179 Galati, Romania
6 Pneumology Department II, Pneumophtisiology Hospital Galati, 800170 Galati, Romania
7 Clinical Medical Department, “Dunarea de Jos” University Galati, 800008 Galati, Romania; manuela.arbune@ugal.ro
8 Infectious Diseases Clinic I, Infectious Diseases Clinic Hospital Galati, 800179 Galati, Romania
* Correspondence: mariana.stuparu@ugal.ro; Tel.: +40-742-208-283
23 8 2024
10 2024
16 5 783793
03 7 2024
20 8 2024
21 8 2024
© 2024 by the authors.
2024
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
COVID-19 and influenza are highly contagious respiratory viral diseases and priority global public health concerns. We conducted a retrospective observational study of COVID-19 and/or influenza hospitalized cases, during 2023. We identified 170 influenza cases, 150 COVID-19 cases and 3 co-infections. Overall, 29.10% of patients had at least one COVID-19 vaccine dose and 4.6% received the seasonal Flu vaccine. The demographic data found older patients in the COVID-19 group and a higher index of the comorbidities, mainly due to chronic heart diseases, hypertension, and diabetes. Fever, chills, and rhinorrhea were more frequently related to influenza, while cough was prevalent in COVID-19. Antibiotics were more used in influenza than COVID-19, either pre-hospital or in-hospital. The mortality rate within the first 30 days from the onset of the respiratory infection was higher in influenza compared to COVID-19. We concluded that the COVID-19 clinical picture in hospitalized patients is changing to influenza-like symptoms. The evolution is variable, related to chronic comorbidities, but influenza had more frequent severe forms. All through 2023, due to poor vaccination rates, COVID-19 and influenza have continued to cause numerous hospitalizations, and a new strategy for efficient vaccinations is required.

viral diseases
SARS-CoV-2
influenza
vaccine
This research received no external funding.
==== Body
pmc1. Introduction

COVID-19 and influenza are viral respiratory illnesses with high contagiousness, constituting priorities for global public health. The public health restricted measures during the early pandemic in 2020–2021 resulted in an impact on the absence of the annual seasonal epidemic of most seasonal respiratory viruses [1]. The current epidemiology of the two infections reports annual recurrences in the case of influenza and a decreasing trend in the COVID-19 pandemic. The dynamics and epidemiological trends in COVID-19 and Flu in six WHO regions from January 2020 to March 2023 were retrospectively described by Wang Q. et al. by using a neural network model. They found that influenza activity was below 10% in the first COVID-19 pandemic year, but gradually increased during the declined Delta SARS-CoV-2 variant, although Delta continues to dominate, while Flu dominance alternated with COVID-19 during the Omicron variant. The activities of influenza and COVID-19 have shown a seesaw effect, due to their reciprocal suppression and competition [2]. Both influenza and coronaviruses are distributed to multiple hosts and co-circulation or co-infections allow genetic reassortment and recombination, resulting in new variants that are able to increase the cross-species transmission. Co-infection could be clinically more severe and the serum cytokines and chemokines could be related to clinical manifestation [3].

Hospitalized cases of COVID-19 continue to be reported, maintaining the risk of the emergence of new viral variants, which can cause waves of illnesses and deaths. Both viral etiological agents, SARS-CoV-2 and the influenza virus, are characterized by antigenic variations that occur over time. As the many viruses with high mutation rates, mutations could emerge at each position in the genome, evolving all possible nucleotides, and continuously produced genetic diversity allows viral escape from the host immunity [4]. Therefore, although COVID-19 and influenza are vaccine-preventable diseases, vaccine protection depends on the match between vaccine components and the antigenic configuration of the circulating viral strains. The symptomatology of influenza and COVID-19 is similar, with fever, dyspnea, dysphagia, rhinorrhea, and myalgia, and specific tests are necessary for differential diagnosis [5]. COVID-19-influenza co-infections have symptoms common to mono-infections, but the more severe progression carries a higher risk than mono-infections [6].

Despite numerous clinical trials, the antiviral treatment of COVID-19 has not yet been standardized, while influenza benefits from firm therapeutic recommendations [7,8]. This study aims to compare the clinical-epidemiological and evolutionary characteristics of hospitalized cases of influenza and COVID-19 in 2023.

2. Materials and Methods

We conducted a retrospective observational study of cases of influenza and COVID-19 admitted between 1 January 2023 and 31 December 2023 in a department of the Clinical Hospital for Infectious Diseases in Galati, located in southeastern Romania. We selected cases diagnosed according to the international classification of diseases from the hospital’s information system with codes U07.1 and J10.0, J10.1, and J10.8. During this period, all patients hospitalized with flu-like symptoms (fever, cough, sore throat, coryza, headache, malaise, myalgia, arthralgia, and/or hypoxemia, dyspnea, tachypnoea) were tested upon admission with rapid tests for both COVID-19 and influenza A/B. The diagnosis of influenza and COVID-19 was based on the case definitions for communicable diseases from the European Union [9].

Hospitalized cases were those complicated and associated with comorbidities at risk of severe progression, but not critical cases, as the hospital does not have an intensive care unit. Cases that worsened to critical forms were transferred to the tertiary emergency hospital. All hospitalized patients signed informed consent to use personal data for research purposes. We collected demographic data, medical history, vaccination history, symptomatology, clinical evolution, and complications during hospitalization. Thirty-day mortality post-hospitalization was assessed through telephone interviews with patients or contact persons listed in the informed consent signed upon admission, according to local procedures. We calculated the Charlson comorbidity index for each patient and compared the overall score value and frequency of the scored comorbidities [10].

The management of patients with COVID-19 and influenza followed the standard of care according to national protocols [11].

The statistical analysis used XL-Stat 2023.5.1. We employed descriptive statistical tests, calculating the frequency, the distribution shape of the values, and the central tendency parameters: mean, median, and standard deviation. We compared the relationship between the characteristics of the COVID-19 group and the influenza group, depending on the type of variables. We used the Mann–Whitney test to compare median differences for numerical variables, such as age, the duration from onset to hospitalization, and the length of hospital stay. Other variables used were ordinal data, compared using odds ratios and Fisher’s Exact Test. The Chi-Square Test of Independence was used to analyze if the association between two categorial variables is significant or not. A p-value of <0.01 was considered statistically significant. Cases with dual infection of COVID-19 and influenza were described distinctly but were not statistically analyzed.

This study received institutional approval from the Medical Council of Clinical Hospital for Infectious Diseases in Galati No. 4/2/23.05.2024 and No. 4/3/23.05.2024.

3. Results

We identified 170 cases of influenza, 150 cases of COVID-19, and 3 cases of combined infections. By type of influenza virus, 90.5% had influenza A virus, and 9.4% had influenza B. Most hospitalized influenza cases were recorded in winter, while COVID-19 cases were predominantly concentrated in summer–autumn (Figure A1).

3.1. Vaccination Status

Out of the total group of patients, 29.10% had received at least one dose of the COVID-19 vaccine, only 4.6% had been vaccinated for seasonal influenza, and 3.4% had been vaccinated for both. Vaccine immunization did not protect 6.9% of the patients hospitalized with influenza and 30.66% of those hospitalized for COVID-19. Additionally, 12.66% of the COVID-19 group reported having had at least one previous episode of COVID-19 in their medical history.

3.2. Demographic Characteristics

The average age of patients with COVID-19 was 63.84 ± 18.7 years [min 9 years; max 90 years], significantly higher compared to 46.81 ± 25.59 years [min 1 year; max 94 years] for patients with influenza (Mann–Whitney test p < 0.001).

Other demographic characteristics highlighted a predominance of women and urban residency in both respiratory infections while there are differences in education and occupation. The COVID-19 group of patients were more educated but less professionally active (Table 1).

3.3. Co-Morbidities

The Charlson Comorbidity Index was significantly higher in patients with COVID-19 than those with influenza: 3.55 ± 2.42 vs. 2.17 ± 2.43 (Mann–Whitney test p < 0.001).

The most reported comorbidities were hypertension, chronic heart failure, cerebrovascular accident, and diabetes mellitus. The patients with COVID-19 were more frequently obese, hypertensive, diabetics, and had a history of cerebrovascular disease than patients with influenza (Table 2).

3.4. Clinical Characteristics

The median duration of symptoms from onset to hospitalization was 2 days, with variations between 1 and 10 days, for COVID-19 and influenza.

Most patients experienced fever and/or chills. The patients with influenza were more likely to present fever (OR = 2.43), chills (OR = 2.04), and rhinorrhea (OR = 3.37), while cough was significantly more frequent in patients with COVID-19 (OR = 2.62). Almost two-thirds of the patients reported headaches, both with COVID-19 and influenza. Dysphagia, myalgia, and asthenia had frequencies between 24% and 37%, but there were no significant differences between the patient groups. Other symptoms identified in both groups included arthralgia, dyspnea, vomiting, diarrhea, abdominal pain, vertigo, and syncope (Table 3).

Anosmia/Ageusia were reported in four patients with COVID-19 and in one patient with influenza. Other symptoms specified only for COVID-19 included dysphonia (3), confusion (2), balance disorders (2), epileptic seizure (1), and epistaxis (1).

3.5. Radiological Characteristics

The main pulmonary radiological changes in COVID-19 were increased interstitial markings 83%, unilateral opacities 7%, and bilateral opacities 7%. Isolated cases reported ground-glass opacities, atelectasis, and pulmonary fibrosis. The distribution of radiological changes in influenza showed 83% interstitial changes, 11% unilateral opacities, 5% bilateral opacities, and isolated cases of pleurisy and pleuritis (Figure A2).

3.6. Antiviral and Antibiotic Treatment

Antivirals were administered to 96% of patients with influenza (Oseltamivir) and 79.3% with COVID-19 (Remdesivir).

Antibiotics were used prior to hospitalization in 39 influenza and 13 COVID-19 patients, and the difference was significant (OR = 3.11; Chi-Square test p < 0.001). During hospitalization, influenza patients also received systemic antibiotics, particularly third generation cephalosporins, more frequently than those with COVID-19 (18.2% versus 2% p < 0.001). During hospitalization, bacterial strains were isolated from only 4% of patients (related to six influenza and seven COVID-19): Klebsiella pneumoniae (3), Escherichia coli (3), Moraxella catharalis (2), Staphylococcus aureus (3), Streptococcus pneumoniae (2), Group B Streptococcus (1), Acinetobacter baumannii (1). Double bacterial isolates were found in two cases. Staphylococcus aureus and Streptococcus pneumoniae were identified in the sputum of a patient with influenza. Additionally, multidrug resistance screening from rectal swabs identified Acinetobacter baumannii and Enterococcus faecium in a patient with COVID-19. Clostridioides difficile diarrhea was present in nine patients.

3.7. Evolution, Complications

The median duration of hospitalization for both infections was 5 days, with variations between 1 and 15 days. Moderate forms of the disease predominated. Severe forms represented 10.7% in COVID-19 and 12.9% in influenza. There were no in-hospital deaths, but the condition worsened and 3 patients with COVID-19 and 11 patients with influenza were transferred to intensive care. The mortality rate within the first 30 days from the onset of the respiratory infection was higher in influenza compared to COVID-19 (Table 4). Most hospitalized cases were pneumonia. Complications such as sepsis, acute respiratory failure, and hepatitis were similar in both COVID-19 and influenza, but nephritis and coagulation disorders were more associated with COVID-19 (Table 4).

3.8. Characteristics of COVID-19 and Influenza Co-Infection

Three cases of concurrent infections of COVID-19 and influenza were reported in December 2023. These cases involved patients over the age of 68: two women and one man from rural areas, with heart failure and atrial fibrillation, unvaccinated for COVID-19 and influenza, and without confirmed prior COVID-19 infections. Fever was absent in all patients, while cough was the constant symptom. The three patients had respiratory failure-complicated pneumonic forms of the disease with complex radiological changes, including bilateral opacities (one case) and bilateral hyper-transparencies (two cases). All patients received both Remdesivir (3 days) and Oseltamivir (5–7 days) without any side effects and showed favorable progress (Table A1).

4. Discussion

The outbreak of the SARS-CoV-2 coronavirus pandemic in 2019 was characterized by explosive morbidity and mortality due to its unusually high transmissibility and virulence. Access to molecular diagnostic techniques enabled the identification of an extraordinary number of genomic sequences, leading to the emergence of distinct variants and phenotypes with specific characteristics regarding transmissibility, severity, and post-infectious immunity. The rate of substitutions in the virus’s molecular evolution, the rate of mutation through host-mediated genome replication errors, or the recombination of various viral genetic structures, which led to the emergence of hybrid variants, can all explain the diversification of SARS-CoV-2 during the pandemic [12].

The initial variant of SARS-CoV-2 was named Alpha, but within a few months, variants of concern (VOC) emerged and spread rapidly: Delta (2020–2021), Omicron BA.1, BA.2, BA.3, and BA.5 (2021), Omicron BA.5 (2022) [13,14,15].

In 2023, the circulation of Alpha, Delta, and Omicron strains was rare, with COVID-19 illnesses being attributed to the emergence of an Omicron subvariant EG5 (Eris). This variant, classified by the World Health Organization as a “variant of interest,” possesses a mutation responsible for evading post-vaccination or post-infection immunity and increasing transmissibility. It contributed to the rapid rise in cases in Romania in the second half of 2023, consistent with the trend observed in our study [16].

Upper respiratory tract symptoms characterized the prevalent variant in 2023, but elderly individuals (over 65 years) and those with immunosuppression may develop severe forms of pneumonia [17].

The circulation of the influenza virus maintains its seasonal character. In 2023, there were two epidemic seasons. From the 2022 to 2023 season, cases were concentrated in January, gradually decreasing until March, with isolated cases in April and May. The 2023–2024 season started late, with a single case in November and slightly increasing in December. In line with the European situation, Influenza Virus A was predominant [18,19].

The low vaccination rates can explain hospitalizations for the two respiratory infections amidst a general reluctance towards vaccination. A national study in Romania in 2023 showed that 28.4% of the general population was vaccinated against COVID-19, compared to 29.1% in our study, and 15.34% were vaccinated for seasonal influenza, compared to 4.6% of our hospitalized patients [20].

Comparative demographic data indicate a higher number of young patients hospitalized with influenza than COVID-19, consistent with active professions. Most hospitalized COVID-19 patients were over 65 years old, but there were also five pediatric cases. Influenza hospitalizations were distributed across all age groups, with the majority under 50 and 15.29% pediatric cases under age 15.

Co-morbidities more frequently associated with COVID-19 included obesity, hypertension, chronic heart failure, and diabetes mellitus, which have been known since earlier in the pandemic as risk factors for severe disease progression [21,22].

The symptoms of COVID-19 and influenza were overlapping, with no pathognomonic clinical features to differentiate between these viruses. A descriptive analytical large study from February 2020 to 2022 reported significant differences in symptoms among different variants of COVID-19, finding positive association with myalgia, cough, taste and smell disorders [23]. Compared to previous years, anosmia/ageusia were no longer indicators for suspected COVID-19 in our study, and they were rarely reported in 2023. Lehfeld A.S. et al. reported altered sense of smell and taste rates decreasing from 23% and 24% during the Delta phase to 7% and 8% in the Omicron phase [24].

The major radiologic findings in COVID-19 are airspace opacities, usually bilateral, peripheral, in the lower fields, but the radiological expression in our study was similar in COVID-19 and influenza, with 83% interstitial changes, followed by bilateral and unilateral opacities [25]. “Ground glass” images, suggestive of COVID-19, were identified in only one case, indicating a change in the clinical-radiological picture associated with new SARS-CoV-2 variants [26].

The use of antibiotics was more restricted for COVID-19 than influenza, similar with other reports [27]. However, Clostridioides difficile diarrhea was more frequent in COVID-19 patients. The greater vulnerability of COVID-19 patients to Clostridioides difficile may be due to the older age of the patients, but especially to the alteration of the intestinal microbiota, consequent to the inflammation of epithelial and stromal cells. Research has shown that SARS-CoV-2 enters cells by binding to the angiotensin-converting enzyme 2 receptor, abundantly found in the gastrointestinal tract [28].

The frequency of respiratory failure and sepsis were similar in both infections, but renal complications and coagulation disorders predominated in COVID-19 patients.

The mortality rate of COVID-19 hospitalizations has decreased worldwide compared to the pandemic’s beginning, but most studies indicate that the 30-day mortality rate remains higher than for influenza. In our study, the 30-day influenza mortality was slightly higher compared to other studies (4.71% vs. 3.7–3.8%) but also higher than COVID-19 mortality. The decrease in the death rate from COVID-19 in hospitalized patients may be due to post-vaccination or post-infection immunity, the decreased virulence of new SARS-CoV-2 variants, and the increased efficiency of patient care [29,30].

A large study compared epidemiology of respiratory viruses in pre-pandemic and during the COVID-19 pandemic. Pre-pandemic bi-annual peak seasonality of influenza was changed during the pandemic, to unclear seasonality, concomitant with decrease in the detection rate of influenza viruses. Moreover, the influenza positivity rates were higher in pediatric ages, either pre-pandemic or during the pandemic, while SARS-CoV-2 affected all ages over age 15 [31].

Co-infections between SARS-CoV-2 and influenza have been reported to be rare (<1%) [32]. The reciprocal circulation of both viruses allows the viral interference, which is characterized by a huge diversity, mainly in tropical regions. Viral competition is a transient inhibitory effect at the host level produced by a virus on a secondary infection by other viruses, mainly sustained interferon pathway activation [33].

In December, the concurrent circulation of influenza viruses and SARS-CoV-2 favored combined infections, which did not differ in clinical expression and severity compared to mono-infections. The incubation and contagiousness of COVID-19 are longer than those of influenza, making it difficult to differentiate between concurrent infections and sequential infections, with influenza superinfection in a patient with prolonged SARS-CoV-2 carriage. The therapy for co-infections is not standardized. Our clinical approach was the administration of Remdesivir for 3 days, combined with Oseltamivir for 5 to 10 days. Drug interactions between Remdesivir and Oseltamivir are not well known, but the estimated risk may be low due to the rapid metabolism of Remdesivir [34,35,36].

Post-respiratory virus outcomes were analyzed in the US, and compared the patients hospitalized with COVID-19 between 2020 and 2022 and seasonal influenza hospitalized between 2015 and 2019. In the COVID-19 group, higher mortality and increased risks of morbid consequences in all organ systems, excepting the lung, were reported. Longer term effects on the pulmonary system were experienced in influenza group [37].

Further research will bring more clinical data for better understanding the viral interactions and the post-infectious long-term consequences of influenza and COVID-19.

Study Limitations

This study’s retrospective design did not allow for the standardized collection of certain data. The diagnosis was based on clinical data and the epidemiological context, with rapid test results being inadequate for confirming influenza according to the current methodology. Molecular investigations for identifying viral genotypes were unavailable for COVID-19 or influenza.

5. Conclusions

The number of COVID-19 cases in 2023 decreased, but the circulation of the virus continues, with the risk of emerging new variants that could cause waves of illnesses and deaths. COVID-19 and influenza continue to be causes of hospitalization due to insufficient vaccination prevention. Currently, the clinical and radiological pictures of the two viruses are overlapping, requiring specific tests for diagnosis. The evolution is variable, depending on age and associated chronic co-morbidities. Influenza more frequently had a worsening progression and a higher death rate than COVID-19. Intensifying health education efforts and extending vaccination are essential to limit the circulation of influenza and SARS-CoV-2, prevent severe forms of infection, and prevent the emergence of new viral variants with increased virulence.

Acknowledgments

This paper was academically supported by “Dunărea de Jos” University, Galați, Romania.

Author Contributions

Conceptualization, M.A. and C.-M.V.; methodology, M.A.; software, C.-M.V. and G.-C.P.; validation, M.S.C., M.-C.V., and G.-C.P.; formal analysis, C.-M.V. and G.-C.P.; investigation, C.-M.V., M.-C.V., and M.A.; resources M.A.; data curation, M.S.C. and M.-C.V.; writing—original draft preparation, C.-M.V., M.S.C., M.-C.V., and G.-C.P.; writing—review and editing, M.A.; visualization, M.S.C.; supervision, M.A.; project administration, M.S.C. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki, for studies involving humans, and approved by the Institutional Board of Clinic Hospital for Infectious Diseases Galati (No.4/2 date of 23 May 2024 and No.4/2 date of 23 May 2024).

Informed Consent Statement

Informed consent was not applicable due to the retrospective nature of this study.

Data Availability Statement

The data presented in this study are available upon request from the corresponding author. The data are not publicly available due to privacy issues.

Conflicts of Interest

The authors declare no conflicts of interest.

Appendix A

Figure A1 Monthly distribution of COVID-19 and Flu cases during 2023.

Figure A2 Comparative radiologic findings in COVID-19 (a) and FLU (b).

idr-16-00060-t0A1_Table A1 Table A1 Summary of Co-infection COVID-19 and Flu (3 patients) in 2023.

	Patient 1	Patient 2	Patient 3	
Gender	F	F	M	
Age (years)	68	83	70	
Vaccine C/F	0/0	0/0	0/0	
Duration from onset to admission (days)	1	4	3	
Fever	No	No	No	
Clinical appearance	Cough
Asthenia	Cough
Asthenia
Chills
Myalgia	Cough
Chills
Myalgia	
Co-morbidities	CHF
Obesity
Depression	CHF
CKD
Obesity hypertension	CHF
COPD	
X-rays findings	Bilateral opacities	Interstitial enhancement
Pachypleuritis
Bilateral hypertransparency
Perihilar bilateral fibrosis	Unilateral opacity
Bilateral hypertransparency
Bronchiectasis	
Complications	RF
Nephritis	RF
Hypercoagulation	RF	
Antivirals (days)	Remdesivir (3)
Oseltamivir (6)	Remdesivir (3)
Oseltamivir (10)	Remdesivir (3)
Oseltamivir (5)	
Hosp. length (days)	11	9	5	
Outcome (discharge)	Improved	Improved	Asymptomatic	
Legend: F—female; M—male; Vaccine C/F—COVID-19 or Flu vaccine; CHF—chronic heart failure; CKD—chronic kidney disease; COPD—chronic obstructive pulmonary disease; RF—respiratory failure.

idr-16-00060-t001_Table 1 Table 1 Demographic characteristics of the patients hospitalized with COVID-19 and Flu.

	COVID-19 (N1 = 150)	Influenza (N2 = 170)	Odds Ratio	Chi-Square Test (p)	
n1	%	n2	%	
Gen	male	61	40.7%	74	43.5%	1.124	0.604	
female	89	59.3%	96	56.5%	
Living area	urban	90	60%	99	58.2%	0.929	0.748	
rural	60	40%	71	41.7%	
Education	illiterate	8	5.3%	31	18.2%	0.172
1.343
1.325	<0.001
0.407
0.295	
4 years	30	20%	30	11.8%	
8 years	48	32%	48	25.3%	
≥12 years	64	42.7%	76	44.70%	
Occupation	employed	25	16.7%	41	24.1%	0.406
3.362	0.002
<0.001	
retired	96	64%	64	37.6%	
unemployed	29	19.3%	65	24.1%	

idr-16-00060-t002_Table 2 Table 2 Comparation of co-morbidities related to COVID-19 vs. Flu.

	COVID-19 (N = 150)	FLU (N = 170)	OR	CI 0.95	Fisher’s Exact Test (p)	
n1	%	n2	%	
Obesity *	58	38.7%	46	27.1%	1.69	1.06; 2.71	0.026	
Hypertension	66	44%	51	30	1.83	1.15; 2.89	0.013	
Charlson Co-morbidities	
MI	4	2.67%	2	1.18%	2.30	0.43; 12.17	0.570	
CHF	26	17.3%	23	13.6%	1.33	0.72; 2.44	0.443	
PVD	1	0.67%	4	2.35%	0.27	0.03; 2.19	0.224	
CVA	20	13.3%	6	3.50%	4.17	1.73; 10.07	0.002	
Dementia	7	4.67%	6	3.53%	1.33	0.44; 4.05	0.814	
COPD	10	6.67%	8	4.71%	1.44	0.55; 3.74	0.604	
CTD	2	1.33%	1	0.59%	2.28	0.21; 23.83	0.906	
Peptic ulcer disease	5	3.33%	1	0.59%	5.82	0.86; 39.44	0.161	
Liver disease	15	10%	11	6.47%	1.60	0.71; 3.59	0.343	
Diabetes mellitus	38	25.3%	15	8.82%	3.50	1.88; 6.51	<0.001	
Hemiplegia	5	3.33%	3	1.76%	1.91	0.46; 7.98	0.589	
CKD	7	4.67%	8	4.71%	0.99	0.35; 2.80	1.198	
Solid tumor	8	5.33%	4	2.35%	2.33	0.71; 7.67	0.269	
Leukemia	1	0.67%	2	1.18%	0.56	0.05; 6.08	1.093	
Lymphoma	2	1.33%	0	0	-	-	-	
AIDS	6	4%	5	2.94%	1.37	0.41; 4.57	0.829	
Legend: * Obesity defined by the body mass index (BMI) ≥ 30 kg/m2; MI: Myocardial infarction; CHF: Chronic heart failure; PVD: Peripheral vascular disease; CVA: Cerebrovascular accident; COPD: Chronic obstructive pulmonary disease; CTD: Connective tissue disease; CKD: Moderate-to-severe chronic kidney disease.

idr-16-00060-t003_Table 3 Table 3 Comparative clinical features of hospitalized COVID-19 vs. Flu during 2023.

	COVID-19 (N = 150)	FLU (N = 170)	OR	CI 0.95	Fisher’s Exact Test (p)	
Fever	87	58%	131	77.1%	2.43	1.5; 3.9	<0.001	
Chills	39	26%	71	41.8%	2.04	1.2; 3.2	0.003	
Headache	50	66.7	59	65.3	1.06	0.6;1.6	0.795	
Myalgia	45	30%	64	37.6%	1.40	0.8; 2.2	0.149	
Arthralgia	14	9.33%	27	15.9%	1.83	0.9;3.6	0.110	
Sore throat	37	24.7%	48	28.2%	1.20	0.7; 1.9	0.552	
Rhinorrhea	10	6.67%	33	19.4%	3.37	1.65; 6.88	0.001	
Cough	62	41.3%	36	21.2%	2.62	1.6; 4.2	<0.001	
Dyspnea	24	16%	15	8.8%	1.96	0.9; 3.87	0.070	
Vomiting	13	8.67%	28	16.5%	2.07	1.0; 4.1	0.053	
Diarrhea	14	9.3%	7	4.1%	2.39	0.9; 5.9	0.097	
Abdominal pain	5	3.3%	1	0.6%	0.17	0.0; 1.16	0.161	
Chest pains	6	4%	6	3.5%	1.13	0.3; 3.6	1.050	
Asthenia	41	27.3%	44	25.9%	0.92	0.5; 1.5	0.866	
Vertigo	9	6%	10	5.8%	0.97	0.3; 2.4	1.14	
Lipothymia	7	4.67%	3	1.76%	0.366	0.0; 1.3	0.243	

idr-16-00060-t004_Table 4 Table 4 Outcome and complications of COVID-19 vs. Flu in hospitalized patients (2023).

	COVID-19 (N = 150)	FLU (N = 170)	OR	CI 0.95	Fisher’s Exact Test (p)	
n1	%	n2	%	
Outcome	
Mild	24	16%	29	17.1%	0.92	0.5; 1.67	0.919	
Medium	112	74.7%	119	70%	0.79	0.4; 1.3	0.421	
Severe	16	10.7%	22	12.9%	0.83	0.4; 1.6	0.651	
Aggravation	3	2%	11	6.47%	3.38	0.9; 11.5	0.088	
Deaths—30 days	4	2.67%	8	4.71%	1.80	0.5; 6.0	0.511	
Complications	
Sepsis	1	0.7%	1	0.6%	1.13	0.0; 18.2	1.437	
Pneumonia	141	94%	151	88.8%	0.50	0.2; 1.1	0.148	
Respiratory failure	15	10%	20	11.8%	0.83	0.4; 1.6	0.747	
Hepatitis	14	9.33	22	12.9%	1.44	0.7; 2.9	0.400	
Nephritis	35	23.3%	13	7.65%	3.67	1.9; 7.0	<0.001	
Hypercoagulation	39	26%	2	1.18%	29.51	10.8; 80.2	<0.001	
Cl. difficile Diarrhea	8	5.3%	1	0.6%	9.52	1.7; 53.4	0.022	

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
==== Refs
References

1. Groves H.E. Piché-Renaud P.P. Peci A. Farrar D.S. Buckrell S. Bancej C. Sevenhuysen C. Campigotto A. Gubbay J.B. Morris S.K. The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A population-based study Lancet Reg. Health Am. 2021 1 100015 10.1016/j.lana.2021.100015 34386788
2. Wang Q. Jia M. Jiang M. Liu W. Yang J. Dai P. Sun Y. Qian J. Yang W. Feng L. Seesaw Effect Between COVID-19 and Influenza From 2020 to 2023 in World Health Organization Regions: Correlation Analysis JMIR Public Health Surveill. 2023 9 e44970 10.2196/44970 37191650
3. Yang J. Gong Y. Zhang C. Sun J. Wong G. Shi W. Liu W. Gao G.F. Bi Y. Co-existence and co-infection of influenza A viruses and coronaviruses: Public health challenges Innovation 2022 3 100306 10.1016/j.xinn.2022.100306 35992368
4. Yewdell J.W. Antigenic drift: Understanding COVID-19 Immunity 2021 54 2681 2687 10.1016/j.immuni.2021.11.016 34910934
5. Tyrrell C.S. Allen J.L.Y. Gkrania-Klotsas E. Influenza: Epidemiology and hospital management Medicine 2021 49 797 804 10.1016/j.mpmed.2021.09.015 34849086
6. Varshney K. Pillay P. Mustafa A.D. Shen D. Adalbert J.R. Mahmood M.Q. A systematic review of the clinical characteristics of influenza-COVID-19 co-infection Clin. Exp. Med. 2023 23 3265 3275 10.1007/s10238-023-01116-y 37326928
7. Dadashi M. Khaleghnejad S. Abedi Elkhichi P. Goudarzi M. Goudarzi H. Taghavi A. Vaezjalali M. Hajikhani B. COVID-19 and Influenza Co-infection: A Systematic Review and Meta-Analysis Front. Med. 2021 8 681469 10.3389/fmed.2021.681469 34249971
8. Guan Z. Chen C. Li Y. Yan D. Zhang X. Jiang D. Yang S. Li L. Impact of Coinfection With SARS-CoV-2 and Influenza on Disease Severity: A Systematic Review and Meta-Analysis Front. Public Health 2021 9 773130 10.3389/fpubh.2021.773130 34957025
9. Decisions Commission Implementing Decision (EU) 2018/945 of 22 June 2018 on the Communicable Diseases and Related Special Health Issues to Be Covered by Epidemiological Surveillance as well as Relevant Case Definitions Official Journal of the European Union. Publications Office of the European Union: Luxembourg, 6 July 2018. L 170/1 Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32018D0945 (accessed on 2 December 2023)
10. Charlson M.E. Carrozzino D. Guidi J. Patierno C. Charlson Comorbidity Index: A Critical Review of Clinimetric Properties Psychother. Psychosom. 2022 91 8 35 10.1159/000521288 34991091
11. Ministerul Sanatatii Protocolul de Tratament al Infecției cu Virusul SARS-CoV-2. Monitorul Oficial, Partea I nr. 576 din 26 Iunie 2023 Available online: https://legislatie.just.ro/public/DetaliiDocument/271637 (accessed on 30 July 2023)
12. Markov P.V. Ghafari M. Beer M. Lythgoe K. Simmonds P. Stilianakis N.I. Katzourakis A. The evolution of SARS-CoV-2 Nat. Rev. Microbiol. 2023 21 361 379 10.1038/s41579-023-00878-2 37020110
13. Tada T. Zhou H. Dcosta B.M. Samanovic M.I. Mulligan M.J. Landau N.R. Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera iScience 2021 24 103341 10.1016/j.isci.2021.103341 34723159
14. Chen D.Y. Chin C.V. Kenney D. Tavares A.H. Khan N. Conway H.L. Liu G. Choudhary M.C. Gertje H.P. O’Connell A.K. Spike and nsp6 are key determinants of SARS-CoV-2 Omicron BA.1 attenuation Nature 2023 615 143 150 10.1038/s41586-023-05697-2 36630998
15. Liu S. Selvaraj P. Sangare K. Luan B. Wang T.T. Spike protein-independent attenuation of SARS-CoV-2 Omicron variant in laboratory mice Cell Rep. 2022 40 111359 10.1016/j.celrep.2022.111359 36075211
16. Markov P.V. Katzourakis A. Stilianakis N.I. Antigenic evolution will lead to new SARS-CoV-2 variants with unpredictable severity Nat. Rev. Microbiol. 2022 20 251 252 10.1038/s41579-022-00722-z 35288685
17. Yadav S. Zaman K. Bashyal P. Bhatta R. Bhandari S. Mohanty A. Sah R. Newer emerging SARS-CoV-2 variant: Omicron EG.5 Ann. Med. Surg. 2023 85 5845 5846 10.1097/MS9.0000000000001386
18. Kissling E. Maurel M. Emborg H.D. Whitaker H. McMenamin J. Howard J. Trebbien R. Watson C. Findlay B. Pozo F. Interim 2022/23 influenza vaccine effectiveness: Six European studies, October 2022 to January 2023 Eurosurveillance 2023 28 2300116 10.2807/1560-7917.ES.2023.28.21.2300116 37227299
19. ECDC Influenza Virus Characterization: Summary Report, Europe, March 2024 WHO Regional Office for Europe and Stockholm and European Centre for Disease Prevention and Control Copenhagen, Denmark 2024 Available online: https://www.ecdc.europa.eu/sites/default/files/documents/influenza-ECDC-WHO-Report-March-2024.pdf (accessed on 1 May 2024)
20. Malița M.A. Manolescu L.S.C. Perieanu V. Babiuc I. Marcov E.C. Ionescu C. Beuran I.A. Prasacu I. Perieanu M.V. Voinescu I. COVID-19 and flu vaccination in Romania, post pandemic lessons in healthcare workers and general population PLoS ONE 2024 19 e0299568 10.1371/journal.pone.0299568 38451954
21. Chatterjee S. Nalla L.V. Sharma M. Sharma N. Singh A.A. Malim F.M. Ghatage M. Mukarram M. Pawar A. Parihar N. Association of COVID-19 with Comorbidities: An Update ACS Pharmacol. Transl. Sci. 2023 6 334 354 10.1021/acsptsci.2c00181 36923110
22. Vasile M.C. Arbune A.A. Lupasteanu G. Vlase C.M. Popovici G.C. Arbune M. Epidemiologic and Clinic Characteristics of the First Wave of the COVID-19 Pandemic in Hospitalized Patients from Galați County J. Clin. Med. 2021 10 4210 10.3390/jcm10184210 34575321
23. Torabi S.H. Riahi S.M. Ebrahimzadeh A. Salmani F. Changes in symptoms and characteristics of COVID-19 patients across different variants: Two years study using neural network analysis BMC Infect. Dis. 2023 23 838 10.1186/s12879-023-08813-9 38017395
24. Lehfeld A.S. Buda S. Haas W. Hauer B. Schulze-Wundling K. Buchholz U. The Changing Symptom Profile of COVID-19 During the Pandemic-Results From the German Mandatory Notification System Dtsch. Ärztebl. Int. 2023 120 420 421 10.3238/arztebl.m2023.0018 37563873
25. Martínez Chamorro E. Díez Tascón A. Ibáñez Sanz L. Ossaba Vélez S. Borruel Nacenta S. Radiologic diagnosis of patients with COVID-19 Radiologia 2021 63 56 73 10.1016/j.rx.2020.11.001 33339622
26. Garrana S.H. Som A. Ndakwah G.S. Yeung T. Febbo J. Heeger A.P. Lang M. McDermott S. Mendoza D.P. Zhang E.W. Comparison of Chest CT Findings of COVID-19, Influenza, and Organizing Pneumonia: A Multireader Study Am. J. Roentgenol. 2021 217 1093 1102 10.2214/AJR.21.25640 33852360
27. Choi Y. Kang M. Shin D.H. Jung J. Choi S.J. Kim N.H. Moon S.M. Song K.H. Kim E.S. Kim H.B. Antibiotic Prescription in Patients With Coronavirus Disease 2019: Analysis of National Health Insurance System Data in the Republic of Korea J. Korean Med. Sci. 2023 38 e189 10.3346/jkms.2023.38.e189 37365725
28. Bachour S.P. Dalal R. Allegretti J.R. The impact of the COVID-19 pandemic on Therap. Adv. Gastroenterol. 2023 16 17562848231165581 10.1177/17562848231165581
29. Portmann L. de Kraker M.E.A. Fröhlich G. Thiabaud A. Roelens M. Schreiber P.W. Troillet N. Iten A. Widmer A. Harbarth S. Hospital Outcomes of Community-Acquired SARS-CoV-2 Omicron Variant Infection Compared With Influenza Infection in Switzerland JAMA Netw. Open 2023 6 e2255599 10.1001/jamanetworkopen.2022.55599 36790812
30. Xie Y. Choi T. Al-Aly Z. Risk of Death in Patients Hospitalized for COVID-19 vs Seasonal Influenza in Fall-Winter 2022–2023 JAMA 2023 329 1697 1699 10.1001/jama.2023.5348 37022720
31. Monamele G.C. Tsafack D.T. Bilounga C.N. Njankouo Ripa M. Nsangou Yogne C. Munshili Njifon H.L. Nkom F. Tamoufe U. Esso L. Koro Koro F. The Detection of Influenza Virus Before and During the COVID-19 Pandemic in Cameroon Influenza Other Respir. Viruses 2024 18 e13313 10.1111/irv.13313 38757747
32. Nowak M.D. Sordillo E.M. Gitman M.R. Paniz Mondolfi A.E. Coinfection in SARS-CoV-2 infected patients: Where are influenza virus and rhinovirus/enterovirus? J. Med. Virol. 2020 92 1699 1700 10.1002/jmv.25953 32352574
33. Lampros A. Talla C. Diarra M. Tall B. Sagne S. Diallo M.K. Diop B. Oumar I. Dia N. Sall A.A. Shifting Patterns of Influenza Circulation during the COVID-19 Pandemic, Senegal Emerg. Infect. Dis. 2023 29 1808 1817 10.3201/eid2909.230307 37610149
34. Gandhi Z. Mansuri Z. Bansod S. Potential Interactions of Remdesivir with Pulmonary Drugs: A Covid-19 Perspective SN Compr. Clin. Med. 2020 2 1707 1708 10.1007/s42399-020-00462-2 32864571
35. Z endehdel A. Bidkhori M. Ansari M. Jamalimoghaddamsiyahkali S. Asoodeh A. Efficacy of oseltamivir in the treatment of patients infected with COVID-19 Ann. Med. Surg. 2022 77 103679 10.1016/j.amsu.2022.103679
36. Sanders J.M. Monogue M.L. Jodlowski T.Z. Cutrell J.B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review JAMA 2020 323 1824 1836 10.1001/jama.2020.6019 32282022
37. Gandhi M. Post-viral sequelae of COVID-19 and influenza Lancet Infect. Dis. 2024 24 218 219 10.1016/S1473-3099(23)00762-4 38104584
